By: Chris Beckham On April 16, the Trump Administration (Administration) initiated a national security investigation into pharmaceuticals and their ingredients under Section 232 of the Trade Expansion Act of 1962 (Section 232).[1] The investigation was initiated one day after President Trump’s executive order to lower drug prices, which called for “promot[ing] a more . . . resilient pharmaceutical value […] The post Section 232 Blues: The Trump Administration’s National Security ...
